Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Commentary|Articles|October 29, 2025
Precision Strategies and Targeted Combinations in GU Oncology: Expert Insights From ESMO 2025
Author(s)Jax DiEugenio
Fact checked by: Chris Ryan
Experts highlight how precision medicine, biomarkers, and targeted combinations presented at ESMO 2025 are shaping the future of GU cancer treatment.
Advertisement
Advertisement
Precision medicine, biomarker-driven treatment selection, and next-generation targeted combinations took center stage in genitourinary (GU) oncology at the
Related to this article
Dabogratinib led to a high rate of responses FGFR3-altered low-grade intermediate-risk non–muscle-invasive bladder cancer.
Faculty convened at an OncLive Scientific Interchange and Workshop to weigh how new regimens should reshape sequencing in prostate cancer.
Focal therapy for prostate cancer has evolved over 2 decades, with advances in imaging, patient selection, treatment modalities, and clinical trials.
The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
Randomized dose-expansion data from the global phase 1 study establish the recommended phase 3 dose for the EGFR x HER3 bispecific ADC in the IZABRIGHT-Lung01 trial.
Final analysis of the phase 3 IMpower030 trial showed a median EFS of 62.8 months versus 34.9 months with placebo plus chemotherapy in stage IIB to IIIB disease.
Advertisement
Advertisement